Skip to main content

Table 2 A summary of organic-mercury exposure from Thimerosal-containing hepatitis B vaccine administration among ASD cases and controls in the VSD database

From: A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States

Group examined Number of cases diagnosed with ASD (%) Number of controls without an ASD (%) Odds ratio (95% CI) p-value
Experiment I     
12.5 μg organic-mercury within 1st month 155 (50.49) 8,161 (31.84)   
    2.18 (1.74–2.73) < 0.00001
0 μg organic mercury within 1st month 152 (49.51) 17,471 (68.16)   
Experiment II     
25 μg organic-mercury within first 2 months 154 (50.49) 8,172 (32.55)   
    2.11 (1.68–2.64) < 0.0001
0 μg organic-mercury within first 2 months 151 (49.51) 16,935 (67.45)   
Experiment III     
37.5 μg organic-mercury within first 6 months 30 (76.92) 1,073 (49.54)   
    3.39 (1.60–7.18) < 0.001
0 μg organic-mercury within first 6 months 9 (23.08) 1,093 (50.46)